Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject's first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
AlphaValue Corporate Services capitalise on the research and credit analysis expertise deployed by AlphaValue with major institutional investors at European level over the past nine years. The proprietary tools and processes enabling AlphaValue Corporate Services to establish a valuation and/or a credit risk assessment are identical to those used by AlphaValue to the benefit of its institutional clients. The only difference is the recognition that a company evaluation cannot be dissociated from the fact that the latter is paying for the service (AlphaValue Corporate Services), as opposed to the investor footing the bill (AlphaValue). AlphaValue’s research tools are characterised by the transparency of the valuation methodologies, their responsiveness to market data and by nine years’ experience of a universe numbering more than 450 European companies. Through its coverage and sector exhaustiveness, AlphaValue ranks alongside the major research houses in Europe and constitutes the only new entrant to the European space in the past decade. This significant presence is reflected in an unrivalled distribution capability via platforms commonly adopted by investors to access research: Factset, Bloomberg, Capital IQ and the numerous websites. AlphaValue is one the largest research contributors to these platforms, to the benefit of AlphaValue Corporate Services issuer clients. The AlphaValue Corporate Services analysts are AlphaValue’s sector specialists. Their robust knowledge of the business models in their sectors enables the rapid generation of incisive, relevant research and advantageous interaction with the management teams.
La société propose une série d'autorisation financière dans les résolutions 7 à 12. Ces autorisations sont maintenues en période d'offre publique, et peuvent ainsi être considérées comme autant de dispositifs anti-OPA. De plus, les résolutions 9 à 11 portent sur une part excessive du capital, et les décotes proposées sont fixées à 20% ce qui excède notre limite de 5%, et constitue un cadeau trop généreux au bénéfice de certains actionnaires, au détriment de tous les actionnaires.La première résolution de l'Assemblée Générale du 20 juin 2019 ayant fait apparaître des capitaux propres inférieurs...
A director at Crossject bought 710,750 shares at 1.763EUR and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...
Taking on-board the Norwegian disposal and near-term market headwinds EPS CHANGE CHANGE IN EPS2020 : CHF 0.56 vs 0.05 +934% 2021 : CHF 0.50 vs 0.63 -19.9% While prevalent macro headwinds result in the normalisation of our earnings estimates, 2020 should nevertheless benefit via the (non-cash) gain (CHF22m) on the disposal of the Norwegian rare earth metal asset.
OPINION CHANGE CHANGE IN OPINIONBuy vs Add CHANGE IN EPS2020 : CHF 5.17 vs 3.80 +35.8% 2021 : CHF 4.68 vs 4.51 +3.77% Following Swissquote's press release today regarding the H1 20 numbers, we have adjusted our numbers for 2020 and going into 2021. H1 20 revenues and profit before tax are indeed 40% and 120% higher yoy. As mentioned in today's Latest, this has come from the sharp increase in market volatility (more trading and opening of new accounts). We expect part of this new business to be sustainable going into 2021 and 2022.
Robust funding, promises in locks & safety TARGET CHANGE CHANGE IN TARGET PRICE€ 2.60 vs 3.17 -17.8% Our target price is mechanically cut by allowing for a c. 23% drop in 2020 revenues and a best guess at zero profits. The small industrial conglomerate entered the COVID-19 crisis with a very strong balance sheet and a cool-headed owner and CEO. It should rebound as quickly as its underlying markets, notably the promising security/safety ones. CHANGE IN EPS2020 : € 0.00 vs 0.21 -98.5% 2021 : € 0.16 vs 0.25 -35.1% 2020 earnings reflect the fact that a near 25% drop in revenue cannot help abs...
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.